Irakli Khuntsaria, Ekaterina Kldiashvili, Mladen Krajacic
Petre Shotadze Tbilisi Medical Academy, Ketevan Tsamebuli avenue 51/2, Tbilisi, 0144, Georgia.
University of Zagreb, Ul. Radoslava Cimermana 88, Zagreb, 10000, Croatia.
BMC Res Notes. 2025 Apr 8;18(1):148. doi: 10.1186/s13104-025-07229-9.
Neutrophils are key players in the innate immune system, responsible for rapid responses to infections through mechanisms such as phagocytosis and the release of reactive oxygen species (ROS). Beyond their role in host defense, neutrophils also contribute to the pathogenesis of various diseases, including infections, metabolic disorders, autoimmune diseases, and cancer. Understanding the immunosuppressive role of neutrophils, particularly through markers like human neutrophil lipocalin (HNL) and the chemokine receptor CXCR3, is crucial for developing targeted therapeutic strategies.
This study involved 200 participants divided into four groups: 50 patients with acute respiratory infection, 50 COVID-19 recovered patients, 50 oncology patients, and 50 healthy donors as controls. Peripheral blood samples were collected and analyzed using enzyme-linked immunoassay (ELISA) to quantify levels of HNL and CXCR3. Data were analyzed using SPSS version 25.0, employing descriptive statistics, the Shapiro-Wilk test for normality, one-way ANOVA for normally distributed variables, and the Kruskal-Wallis test for non-normally distributed variables. Post-hoc comparisons were conducted using Tukey's HSD and Dunn's tests.
CXCR3 levels were stable across groups, with no significant differences found. Acute respiratory infection patients had an average CXCR3 level of 150 ± 20 pg/ml, while COVID-19 recovered patients had slightly lower levels at 140 ± 18 pg/ml. Oncology patients had elevated CXCR3 levels at 160 ± 22 pg/ml, similar to healthy donors at 150 ± 19 pg/ml. HNL levels varied more, with COVID-19 recovered patients showing notably lower levels (100 ± 12 ng/ml) compared to other groups. Oncology patients exhibited higher HNL levels, especially those with prostate cancer (150 ± 20 ng/ml).
The findings highlight the consistent expression of CXCR3 across various conditions, making it a reliable marker for immune response assessment. The distinct HNL profiles, particularly the lower levels in COVID-19 recovered patients and higher levels in prostate cancer patients, suggest unique neutrophil activities and immune responses. These insights into neutrophil-mediated immunosuppression and inflammation could inform the development of targeted therapies for infections, cancer, and autoimmune diseases. Further research is needed to elucidate the specific mechanisms underlying neutrophil-induced immunosuppression.
中性粒细胞是先天性免疫系统的关键参与者,通过吞噬作用和活性氧(ROS)释放等机制对感染做出快速反应。除了在宿主防御中的作用外,中性粒细胞还在包括感染、代谢紊乱、自身免疫性疾病和癌症在内的各种疾病的发病机制中发挥作用。了解中性粒细胞的免疫抑制作用,特别是通过人类中性粒细胞脂质运载蛋白(HNL)和趋化因子受体CXCR3等标志物来了解其免疫抑制作用,对于制定有针对性的治疗策略至关重要。
本研究纳入200名参与者,分为四组:50例急性呼吸道感染患者、50例新冠康复患者、50例肿瘤患者和50名健康供者作为对照。采集外周血样本,采用酶联免疫吸附测定(ELISA)分析以量化HNL和CXCR3水平。使用SPSS 25.0版软件进行数据分析,采用描述性统计、Shapiro-Wilk正态性检验、对正态分布变量采用单因素方差分析以及对非正态分布变量采用Kruskal-Wallis检验。事后比较采用Tukey's HSD检验和Dunn检验。
CXCR3水平在各组中保持稳定,未发现显著差异。急性呼吸道感染患者的CXCR3平均水平为150±20 pg/ml,而新冠康复患者的水平略低,为140±18 pg/ml。肿瘤患者的CXCR3水平升高,为160±22 pg/ml,与健康供者的150±19 pg/ml相似。HNL水平变化更大,新冠康复患者的水平(分别为100±12 ng/ml)明显低于其他组。肿瘤患者表现出较高的HNL水平,尤其是前列腺癌患者(150±20 ng/ml)。
研究结果突出了CXCR3在各种情况下的一致表达,使其成为评估免疫反应的可靠标志物。不同的HNL谱,特别是新冠康复患者中较低的水平和前列腺癌患者中较高的水平,表明中性粒细胞具有独特的活性和免疫反应。这些对中性粒细胞介导的免疫抑制和炎症的见解可为感染、癌症和自身免疫性疾病的靶向治疗发展提供参考。需要进一步研究以阐明中性粒细胞诱导免疫抑制的具体机制。